Regular physical activity plays a crucial role in maintaining a healthy weight, but some people may lose more weight through exercise than others. A recent study conducted by researchers from Kobe University in Japan suggests that individuals who lose weight slowly with regular physical activity may be lacking variants of a specific protein known as PGC-1α. This protein helps regulate the body’s metabolism and response to short-term exercise, leading to more efficient energy consumption in muscles. The research findings may lay the groundwork for a new class of weight loss medications in the future. Published in the journal Molecular Metabolism, the study utilized both mouse and human models to delve deeper into the impact of PGC-1α on exercise and its effects on the body.
PGC-1α is a transcription coactivator protein that induces gene expression related to mitochondria, fatty acid oxidation, and thermogenesis, promoting energy efficiency in muscles. When individuals exercise, the expression of PGC-1α increases in skeletal muscle, leading to efficient energy consumption. Previous research has identified additional variants of the PGC-1α protein, referred to as “b” and “c,” which are produced in muscles in significantly higher amounts during exercise compared to the traditional “a” version. Individuals lacking these variants showed reduced fat burning during and after exercise, highlighting the importance of PGC-1α in the body’s response to physical activity.
In research involving both mice and human test subjects, individuals with the “b” and “c” versions of the PGC-1α protein exhibited increased oxygen consumption and lower body fat percentage compared to those lacking these variants. This effect was observed in both healthy individuals and those with type 2 diabetes. The study findings demonstrated that the absence of the “b” and “c” versions of the protein led to reduced energy expenditure during exercise and weight gain even under normal conditions. This insight could have significant implications for the development of new weight loss medications that target the PGC-1α protein variants to promote efficient energy consumption and weight loss.
The study’s lead author, Wataru Ogawa, MD, PhD, highlighted the potential of utilizing the findings to develop novel weight loss medications that differ from existing drugs like glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy. While current anti-obesity drugs focus on suppressing appetite to aid in weight loss, a medication that increases the expression of PGC-1α “b” and “c” variants could promote weight loss independent of dietary restrictions. This novel approach represents a new class of weight loss therapy that targets energy expenditure in muscles, offering potential benefits for individuals seeking effective and sustainable weight loss solutions.
Dr. Mir Ali, a board-certified bariatric surgeon, acknowledged the importance of genetics in weight management and emphasized the role of diet in achieving substantial weight loss results. While exercise contributes to overall health and weight management, Dr. Ali stressed the significance of a balanced diet in achieving weight loss goals. Understanding the genetic factors influencing weight loss through exercise could lead to the development of improved exercise therapies and potentially new anti-obesity medications that mimic the effects of physical activity. Ongoing research aims to further explore the variability in PGC-1α expression among individuals and identify substances that can increase the levels of beneficial protein variants, paving the way for innovative approaches to combating obesity and promoting overall well-being.
